Regarding HF patients with preserved ejection fraction, the EMPEROR-Preserved study [86] evaluated the efficacy and safety of the administration of empagliflozin 10 mg versus a placebo in HF patients with preserved ejection fraction defined as ejection fraction greater than 40%, with proven elevation of natriuretic peptides (NT-proBNP greater than 300 pg/mL in sinus rhythm or greater than 900 pg/mL in atrial fibrillation) and NYHA II-IV functional class. This evidence concerns the gene NPPB and hydrops fetalis.